| Multiple Sclerosis, Relapsing-Remitting
Mayzent vs Rebif
Side-by-side clinical, coverage, and cost comparison for multiple sclerosis, relapsing-remitting.Deep comparison between: Mayzent vs Rebif with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRebif has a higher rate of injection site reactions vs Mayzent based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rebif but not Mayzent, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Mayzent
Rebif
At A Glance
Oral
Daily
S1P receptor modulator
SC injection
Three times per week
Interferon beta-1a
Indications
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- active secondary progressive multiple sclerosis
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
Dosing
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, active secondary progressive multiple sclerosis 2 mg orally once daily (CYP2C9 *1/*1, *1/*2, or *2/*2) or 1 mg orally once daily (CYP2C9 *1/*3 or *2/*3), each initiated with a dose titration regimen; administer tablets whole, do not split, crush, or chew.
Clinically isolated syndrome, Multiple Sclerosis Relapsing-Remitting, Multiple Sclerosis Secondary Progressive 22 mcg or 44 mcg SC three times per week; titrate starting at 20% of prescribed dose over a 4-week period to the targeted dose; administer at the same time on the same three days at least 48 hours apart each week.
Contraindications
- CYP2C9 *3/*3 genotype
- Myocardial infarction, unstable angina, stroke, TIA, decompensated heart failure requiring hospitalization, or Class III or IV heart failure within the last 6 months
- Mobitz type II second-degree, third-degree AV block, or sick sinus syndrome without a functioning pacemaker
- History of hypersensitivity to natural or recombinant interferon beta, human albumin, or any other component of the formulation
Adverse Reactions
Most common (>=10%) headache, hypertension, transaminase increased
Serious infections, progressive multifocal leukoencephalopathy, macular edema, bradyarrhythmia and AV conduction delays, liver injury, cutaneous malignancies, posterior reversible encephalopathy syndrome, fetal risk
Postmarketing progressive multifocal leukoencephalopathy
Most common Injection site reaction, influenza-like symptoms, headache, fatigue, fever, leukopenia, elevated liver enzymes (SGPT, SGOT), myalgia, back pain, abdominal pain, depression
Serious Depression and suicide, hepatic injury, anaphylaxis and other allergic reactions, injection site necrosis, decreased peripheral blood counts, thrombotic microangiopathy, pulmonary arterial hypertension, seizures
Postmarketing Drug-induced lupus erythematosus, autoimmune hepatitis, retinal vascular disorders, pulmonary arterial hypertension, erythema multiforme, Stevens-Johnson syndrome, hemolytic anemia
Pharmacology
Siponimod is an S1P receptor modulator that binds with high affinity to S1P receptors 1 and 5, blocking lymphocyte egress from lymph nodes and reducing peripheral blood lymphocyte counts; the therapeutic mechanism in multiple sclerosis is unknown but may involve reduction of lymphocyte migration into the central nervous system.
Interferon beta-1a; the exact mechanism(s) by which REBIF exerts its therapeutic effects in multiple sclerosis is unknown, but it is a recombinant form of human interferon beta produced in Chinese Hamster Ovary cells with an amino acid sequence identical to natural fibroblast-derived human interferon beta.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Mayzent
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
Rebif
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
UnitedHealthcare
Mayzent
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (4/8)
Rebif
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Mayzent
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Rebif
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
MayzentView full Mayzent profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.